Display options
Cite
Chrisp P. Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2007;2(1):15-30
Chrisp, P. (2007). Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. Core evidence, 2(1), 15-30.
Chrisp, Paul. "Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting." Core evidence vol. 2,1 (2007): 15-30.
Chrisp P. Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting. Core Evid. 2007 Mar 31;2(1):15-30. PMID: 21221195; PMCID: PMC3012554.
Copy Download .nbib Format: NLM
Share it on

Core Evid. 2007 Mar 31;2(1):15-30.

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.

Core evidence

Paul Chrisp

Affiliations

  1. Core Medical Publishing, Knutsford, UK.

PMID: 21221195 PMCID: PMC3012554

Abstract

INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) represents a significant burden on patients and healthcare systems. Despite the introduction of serotonin antagonists, many patients still experience CINV, particularly delayed symptoms occurring more than 24 hours after chemotherapy. Aprepitant is a selective neurokinin-1 (NK(1)) receptor antagonist approved for use with other antiemetics to prevent CINV caused by moderately to highly emetogenic chemotherapy.

AIMS: To review the evidence underlying the use of aprepitant to prevent CINV.

EVIDENCE REVIEW: In patients receiving moderately and highly emetogenic chemotherapy, adding aprepitant to standard antiemetic therapy with dexamethasone and a serotonin antagonist significantly improved control of CINV. The degree of control of delayed CINV was particularly pronounced, and effectiveness was more likely to be maintained in multiple cycles compared with standard therapy. Nausea was generally less frequent among patients taking aprepitant. More patients receiving aprepitant were satisfied with their treatment and reported minimal/no impact of CINV on daily activities. Aprepitant appears to be well tolerated, with fatigue being the most commonly reported adverse event. The drug is an inhibitor and inducer of cytochrome P450 (CYP) 3A4, resulting in contraindications and caution with some concomitant medication. Limited economic evidence suggests that a proportion of the acquisition cost of aprepitant may be offset by savings in overall direct costs of managing CINV.

PLACE IN THERAPY: The evidence supports the recommended use of aprepitant in clinical guidelines for the prevention of CINV due to highly emetogenic chemotherapy, and its recently approved role in regimens with moderate risk. It is particularly useful for delayed symptoms.

Keywords: aprepitant; chemotherapy; evidence; nausea; vomiting

References

  1. N Engl J Med. 1999 Jan 21;340(3):190-5 - PubMed
  2. Support Care Cancer. 2005 Feb;13(2):85-96 - PubMed
  3. J Clin Oncol. 2003 Nov 15;21(22):4105-11 - PubMed
  4. Cancer. 2005 Aug 15;104(4):864-8 - PubMed
  5. Pharmacoeconomics. 2001;19(9):955-67 - PubMed
  6. Expert Rev Anticancer Ther. 2005 Dec;5(6):963-72 - PubMed
  7. Ann Pharmacother. 2005 Jan;39(1):77-85 - PubMed
  8. Eur J Cancer. 2005 Jun;41(9):1278-85 - PubMed
  9. Clin J Oncol Nurs. 2002 Mar-Apr;6(2):94-102 - PubMed
  10. Support Care Cancer. 2005 Feb;13(2):80-4 - PubMed
  11. Cancer. 2002 Jun 1;94(11):3032-41 - PubMed
  12. Oncology. 1992;49(4):295-304 - PubMed
  13. Support Care Cancer. 2001 Nov;9(8):611-8 - PubMed
  14. J Clin Oncol. 1999 Jan;17(1):344-51 - PubMed
  15. Cancer. 2003 May 1;97(9):2290-300 - PubMed
  16. J Clin Oncol. 1999 Sep;17(9):2971-94 - PubMed
  17. J Clin Oncol. 2003 Nov 15;21(22):4112-9 - PubMed
  18. J Clin Oncol. 2001 Mar 15;19(6):1759-67 - PubMed
  19. Onkologie. 2006 Dec;29(12):557-61 - PubMed
  20. CMAJ. 1993 Aug 1;149(3):296-302 - PubMed
  21. Int J Technol Assess Health Care. 2004 Summer;20(3):289-95 - PubMed
  22. J Clin Oncol. 2003 Apr 1;21(7):1373-8 - PubMed
  23. Cleve Clin J Med. 2002 Aug;69(8):609-10, 612, 615-7 - PubMed
  24. Ann Oncol. 2005;16 Suppl 1:i77-9 - PubMed
  25. Clin Ther. 2003 May;25(5):1407-19 - PubMed
  26. Ann Pharmacother. 2005 Nov;39(11):1903-10 - PubMed
  27. Support Care Cancer. 2006 Apr;14(4):354-60 - PubMed
  28. J Clin Oncol. 2005 Apr 20;23(12):2822-30 - PubMed
  29. Pediatr Blood Cancer. 2005 Nov;45(6):857-60 - PubMed
  30. Eur J Cancer. 2004 Feb;40(3):403-10 - PubMed
  31. Cancer. 2005 Oct 1;104(7):1548-55 - PubMed
  32. Ann Oncol. 2006 Jun;17(6):1000-6 - PubMed
  33. J Clin Oncol. 2006 Jun 20;24(18):2932-47 - PubMed
  34. Support Care Cancer. 2009 Aug;17(8):1065-70 - PubMed
  35. Cancer. 2003 Jun 15;97(12):3090-8 - PubMed
  36. Clin J Oncol Nurs. 2005 Feb;9(1):77-84 - PubMed
  37. Ann Oncol. 1998 Jul;9(7):759-65 - PubMed
  38. Ann Oncol. 2004 Mar;15(3):526-36 - PubMed
  39. J Clin Oncol. 2001 Apr 1;19(7):2091-7 - PubMed
  40. Br J Cancer. 1999 May;80(3-4):412-8 - PubMed

Publication Types